Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

American Heart Journal

Volumn 138, Issue 1 I, 1999, Pages 151-155

  Murdock, D K ^a   Murdock, A K ^a   Murdock, R W ^a   Olson, K J ^a   Frane, A M ^a   Kersten, M E ^a   Joyce, D M ^a   Gantner, S E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032788490     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70261-9     Document Type: Article

References (27)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, et al for the CARE Investigators. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995;76:98C-106C.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarland PW, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. The Simvastatin Pravastatin Study Group. A comparison of the efficacy and safety of simvastatin and pravastatin in the treatment of hyper-cholesterolemia. Am J Cardiol 1993;71:1408-14.
5. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987;317:1237-45.
6. Manninen V, Tenkanen L, Koskinen P, Huttunen J, Manttari M, Heinonen O, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease in the Helsinki heart study. Circulation 1992;85:37-45.
7. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
8. Schectman G, Jan Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Cardiol 1996;100:197-204.
9. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109:25-32.
10. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-5.
11. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990;l12:228-30.
12. Van Puijenbroek EP, Du Buf-Vereijken PWG, Spooren PFMJ, Van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Int Med 1996;240:403-4.
13. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin gemfibrozil therapy. South Med J 1997;90:546-7.
14. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998;81(3):368-9.
15. Vanhanen HT, Tatu A, Miettinen TA. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis 1995:115;135-46.
16. Smit JWA, Jansen GH, de Bruin TWA, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995;126A-128A.
17. Pasternak RC, Brown LF, Stone PH, Silverman DI, Gibson M, Sacks FM for the Harvard Atherosclerosis Reversibility Project (HARP) study group. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels: a randomized, placebo-controlled trial. Ann Intern Med 1996;125:529-40.
18. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 194;74:499-500.
19. Illingworth DR, Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholestrolemia. Circulation 1989;79:590-6.
20. Athyros V, Papageorgiou A, Hagikonstantinou H, Papadopoulos G, Zamboulis C, Kontoponlos A. Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidemia. Drug Invest 1994;7:134-42.
21. Da Col PG, Fonda M, Fisicaro M. Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia. Curr Ther Res 1993;53:473-83.
22. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20.
23. Wirebaugh SR, Shapiro ML, McIntyre TH, Whitney EJ. A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin. Pharmacotherapy 1992;12:445-50.
24. Athyros V, Papageorgiou A, Hagikonstandinou H, Didangelos T, Carina M, Kranitsas D, et al. Safety and efficacy of long-term statinfibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608-13.
25. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of cholesterol in plasma, without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
26. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Int Med 1991;151:43-9.
27. Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol 1998;82(3):311-6.